Textbook oncologic outcomes following pancreatoduodenectomy in patients with pancreatic adenocarcinoma: A high-volume center study

doi:10.3748/wjg.v32.i20.119062

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 20

This Article

(24)

(29)

(0)

(449)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 28, 2026; 32(20): 119062
Published online May 28, 2026. doi: 10.3748/wjg.v32.i20.119062

Table 1 Demographic data and clinical characteristics of open pancreaticoduodenectomy and laparoscopic pancreaticoduodenectomy patients, mean ± SD/n (%)

Characteristic	LPD (n = 144)	OPD (n = 144)	Total (n = 288)	P value
Sex (male)	84 (58.3)	87 (60.4)	171 (59.4)	0.719
Age (years)	59.6 ± 8.3	58.5 ± 9.2	59.1 ± 8.8	0.307
BMI (kg/m²)	21.9 ± 2.4	21.9 ± 3.0	21.9 ± 2.7	0.987
Diabetes	17 (11.8)	18 (12.5)	35 (12.2)	0.857
Cardiovascular disease	32 (22.2)	31 (21.5)	63 (21.9)	0.887
ASA score
I	9 (6.2)	8 (5.6)	17 (5.9)	0.955
II	92 (63.9)	94 (65.3)	186 (64.6)
III	43 (29.9)	42 (29.2)	85 (29.5)
Neutrophil count (× 10⁹/L), median (IQR)	3.4 (2.6, 4.3)	3.2 (2.6, 4.7)	3.4 (2.6, 4.4)	0.937
Lymphocyte count (× 10⁹/L), median (IQR)	1.3 (1.1, 1.7)	1.3 (1.0, 1.7)	1.3 (1.0, 1.7)	0.661
Mononuclear cell count (× 10⁹/L), median (IQR)	0.4 (0.4, 0.6)	0.5 (0.4, 0.6)	0.5 (0.4, 0.6)	0.293
Platelet count (× 10⁹/L), median (IQR)	211.0 (167.0, 266.5)	218.5 (181.5, 259.5)	214.0 (176.0, 265.0)	0.529
Serum albumin (g/L), median (IQR)	38.5 (36.5, 40.8)	38.0 (35.6, 40.4)	38.2 (35.9, 40.5)	0.155
PLR, median (IQR)	160.5 (120.0, 216.4)	161.7 (124.6, 226.3)	160.8 (123.1, 222.2)	0.659
NLR, median (IQR)	2.5 (1.8, 3.4)	2.6 (1.8, 3.7)	2.6 (1.8, 3.4)	0.517
PNI, median (IQR)	45.6 (42.2, 48.3)	45.0 (42.3, 48.0)	45.4 (42.2, 48.1)	0.371
SII, median (IQR)	516.9 (363.3, 780.5)	549.4 (354.5, 836.6)	535.5 (359.5, 809.5)	0.557
NPS, median (IQR)	2.0 (2.0, 3.0)	3.0 (2.0, 3.0)	2.0 (2.0, 3.0)	0.240
CONUT score, median (IQR)	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	2.0 (1.0, 3.0)	1.000
ALT (U/L), median (IQR)	124.5 (43.0, 266.5)	115.0 (52.5, 245.0)	118.5 (50.0, 254.5)	0.558
AST (U/L), median (IQR)	82.0 (36.0, 188.0)	77.0 (36.5, 140.0)	78.0 (36.0, 165.5)	0.548
ALP (U/L), median (IQR)	254.0 (119.5, 454.5)	296.0 (143.5, 476.0)	277.0 (131.5, 462.0)	0.331
γ-GT (U/L), median (IQR)	460.5 (134.0, 764.0)	463.0 (141.5, 908.0)	462.5 (136.0, 832.0)	0.494
TBIL (μmol/L), median (IQR)	100.1 (17.9, 203.2)	123.2 (34.5, 198.2)	118.5 (24.2, 201.2)	0.373
DBIL (μmol/L), median (IQR)	85.0 (9.9, 163.7)	109.3 (24.5, 162.4)	95.4 (16.0, 163.6)	0.397
Serum total cholesterol level (mmol/L), median (IQR)	4.5 (3.8, 5.3)	4.8 (3.7, 6.0)	4.6 (3.8, 5.7)	0.293
CA19-9 (U/mL), median (IQR)	122.7 (37.2, 361.9)	147.1 (36.8, 579.2)	141.3 (37.0, 416.1)	0.156
CEA (ng/mL), median (IQR)	2.8 (1.8, 4.0)	3.3 (2.1, 5.3)	3.0 (2.0, 4.7)	0.013^a

^aP < 0.05.

OPD: Open pancreaticoduodenectomy; LPD: Laparoscopic pancreaticoduodenectomy; ASA: American Society of Anesthesiologists; BMI: Body mass index; PLR: Platelet to lymphocyte ratio; NLR: Neutrophil to lymphocyte ratio; IQR: Interquartile range; SII: Systemic immune inflammation index; PNI: Prognostic nutritional index; NPS: Naples prognostic score; CONUT: Controlling nutritional status; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; γ-GT: γ-glutamyl transferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.

Full Size Table

Citation: Zhang JZ, Guo XY, Zhang ZW, Zhu DS, Zhang Z, Zheng H, Guo T, Yu YH, Huang XR. Textbook oncologic outcomes following pancreatoduodenectomy in patients with pancreatic adenocarcinoma: A high-volume center study. World J Gastroenterol 2026; 32(20): 119062
URL: https://www.wjgnet.com/1007-9327/full/v32/i20/119062.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i20.119062

Zhang JZ, Guo XY, Zhang ZW, Zhu DS, Zhang Z, Zheng H, Guo T, Yu YH, Huang XR. Textbook oncologic outcomes following pancreatoduodenectomy in patients with pancreatic adenocarcinoma: A high-volume center study. World J Gastroenterol 2026; 32(20): 119062 [DOI: 10.3748/wjg.v32.i20.119062]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.